New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy.
Although standard therapy for AML has been relatively constant over the past 2 decades, this may be changing with enhanced technologies allowing for the classification of acute myeloid leukemia (AML) into molecularly distinct subsets. Some specific subsets of AML have an excellent prognosis in response to standard therapy, whereas the poor prognosis of AML associated with specific sets of mutations or chromosomal anomalies requires the development of new therapies. Elucidation of the molecular pathogenesis of AML has led to the development of therapies that affect signaling, apoptosis, protein and intermediate metabolism, the surface of the leukemia cell, leukemia cell/stromal interaction, and epigenetic regulation of gene expression.
Division of Hematology/Oncology, Northwestern University-Feinberg School of Medicine, Chicago, IL, USA.
Irum
I
Khan
Jessica K
JK
Altman
Jonathan D
JD
Licht
D017209:Apoptosis / Q000235:genetics; D002869:Chromosome Aberrations; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000628:therapy; D008745:Methylation; D009154:Mutation; D057089:Pathology, Molecular; D011379:Prognosis; D015398:Signal Transduction; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors / Q000235:genetics
D056572:Histone Deacetylase Inhibitors; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3